1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Mucositis - Pipeline Review, H1 2014

Mucositis - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 46 pages

Mucositis - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Mucositis - Pipeline Review, H1 2014’, provides an overview of the Mucositis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucositis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mucositis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Mucositis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mucositis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mucositis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mucositis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Mucositis - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mucositis Overview 6
Therapeutics Development 7
Pipeline Products for Mucositis - Overview 7
Pipeline Products for Mucositis - Comparative Analysis 8
Mucositis - Therapeutics under Development by Companies 9
Mucositis - Therapeutics under Investigation by Universities/Institutes 10
Mucositis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Mucositis - Products under Development by Companies 13
Mucositis - Products under Investigation by Universities/Institutes 14
Mucositis - Companies Involved in Therapeutics Development 15
Piramal Enterprises Limited 15
Avaxia Biologics, Inc. 16
Tosk, Inc. 17
Rottapharm|Madaus 18
SciDose LLC 19
Mucositis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
P-276 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
CR-3294 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
TK-112690 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Small Molecule For Mucositis - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Melatonin - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
AVX-470 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Mucositis - Recent Pipeline Updates 36
Mucositis - Dormant Projects 38
Mucositis - Discontinued Products 39
Mucositis - Product Development Milestones 40
Featured News and Press Releases 40
Sep 06, 2012: Research Shows Rapamycin Could Protect Against Sore Mouth After Radiotherapy 40
Aug 02, 2011: Access Pharmaceuticals MuGard Added To Humana's Pharmacy Drug Benefit Network 40
Jul 13, 2011: BioAlliance Announces Validation Of Orphan Drug Designation Application For Clonidine Lauriad 41
Jun 24, 2011: BioAlliance Pharma Submits Application For Orphan Medicinal Product Designation For Clonidine Lauriad In Europe And US 41
Jun 04, 2011: SciClone's SCV-07 Demonstrates Antitumor Activity In Various Cancer Xenograft Studies In Mice 41
May 18, 2011: SciClone To Present New Preclinical Data On SCV-07 At 2011 ASCO Annual Meeting 42
Feb 09, 2011: Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential 43
Mar 31, 2010: PolyMedix Completes Phase IB Clinical Study With Antibiotic PMX-30063 43
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables

Number of Products under Development for Mucositis, H1 2014 7
Number of Products under Development for Mucositis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Mucositis - Pipeline by Piramal Enterprises Limited, H1 2014 15
Mucositis - Pipeline by Avaxia Biologics, Inc., H1 2014 16
Mucositis - Pipeline by Tosk, Inc., H1 2014 17
Mucositis - Pipeline by Rottapharm|Madaus, H1 2014 18
Mucositis - Pipeline by SciDose LLC, H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Mucositis Therapeutics - Recent Pipeline Updates, H1 2014 36
Mucositis - Dormant Projects, H1 2014 38
Mucositis - Discontinued Products, H1 2014 39

List of Figures

Number of Products under Development for Mucositis, H1 2014 7
Number of Products under Development for Mucositis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • December 2016
    18 pages
  • Therapy  

  • Netherlands  

    Canada  

View report >

Therapy Market and Blood Disease Statistics

  • December 2016
    8 pages
  • Therapy  

    Blood Disease  

View report >

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.